ASTEPRO (azelastine hydrochloride) by Viatris (2) is hydrochloride, a phthalazinone derivative, exhibits histamine h 1 -receptor antagonist activity in isolated tissues, animal models, and humans. First approved in 2008.
Drug data last refreshed 51m ago · AI intelligence enriched 1w ago
ASTEPRO is an azelastine hydrochloride nasal spray, a selective histamine H1-receptor antagonist delivered via metered nasal spray. It is indicated for allergic rhinitis and functions as a rapid-onset antihistamine with active metabolites that extend therapeutic duration. The racemic mixture formulation targets patients seeking non-sedating intranasal allergy relief.
Product approaching loss of exclusivity with moderate competitive pressure; brand team focus shifting toward transition planning and generic mitigation strategies.
hydrochloride, a phthalazinone derivative, exhibits histamine H 1 -receptor antagonist activity in isolated tissues, animal models, and humans. Azelastine hydrochloride Nasal Spray is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis
Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
Worked on ASTEPRO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
ASTEPRO represents a late-lifecycle commercial asset with limited hiring momentum and declining career development opportunities as patent expiration approaches. Professionals joining this team should expect focus on margin protection, generic transition planning, and potential redeployment post-LOE rather than brand growth initiatives.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo